Apremilast may have some cardiometabolic benefits in patients with psoriasisSeptember 27, 2022PsoriasisPsoriatic ArthritisMixed Topics
Psoriasis, psoriatic arthritis insurance coverage remains restrictiveSeptember 26, 2022Psoriatic ArthritisPsoriasis
Apremilast alleviates severe psoriasis in some children, data showSeptember 20, 2022PsoriasisPsoriatic ArthritisPediatrics
Brodalumab suicide risk similar to other biologics, postmarket study findsSeptember 19, 2022PsoriasisPsoriatic ArthritisMixed Topics
Sustained response at 2 years reported for newly approved oral psoriasis agentSeptember 15, 2022PsoriasisPsoriatic Arthritis
FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasisSeptember 12, 2022PsoriasisPsoriatic Arthritis
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?September 8, 2022Psoriatic ArthritisPsoriasis
FDA okays spesolimab, first treatment for generalized pustular psoriasisSeptember 2, 2022PsoriasisRare Diseases
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depthAugust 29, 2022COVID-19 UpdatesPsoriatic ArthritisPsoriasisInfectious Diseases
Asian patients with psoriasis have shortest visits, study showsAugust 24, 2022PsoriasisPsoriatic ArthritisDiversity in Medicine
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration formAugust 17, 2022Psoriatic ArthritisPediatricsPsoriasis
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review revealsAugust 15, 2022Psoriatic ArthritisPediatricsRare DiseasesPsoriasis
Study suggests psoriasis and PsA are underdiagnosed in underserved groupsAugust 12, 2022PsoriasisPsoriatic Arthritis
Topical roflumilast approved for psoriasis in adults and adolescentsAugust 1, 2022PsoriasisPsoriatic Arthritis
